New Ligands and Inhibitors

• 5118 · PDF In silico discovery of potent small molecule inhibitors targeting the AR N-terminal domain for treating castration-resistant prostate cancer Patrick Kunz, Thomas Alanine, Babette Schade, Ben Cossins, Sandro Bottaro, Daniele Peterle, Flavia Giamogante, Elia Gamba, Sasha Soldati, Nathalie Wyss, Lixin Yang, Michele Invernizzi, Michael Habeck, Rudy Rubini, Melissa Kachura, Dmitry Dmitry Ryzhenkov, Matteo Cerrina, Fabio Airoldi, Valentina Ceserani, Alice Santopolo, Heidi Derks, Stefano Ruschetta, Andrew Allen, David Lowe, Carlo Fisicaro, Ken Carson, Patrik Foerch, Kevin Sprott, Kamil Tamiola
• 5119 · PDF P015, a highly selective PARP7&12 dual inhibitor Jinwen Huang, Hao Huang, Steve Shen
• 5120 · PDF Design and discovery of BH-501242, a novel pan-KRAS on/off inhibitor targeting KRAS switch II pocket Eugene Rui, Nancy Ling, Wei Deng, Ping Jiang, Zhenping Wang, Yue Hu, Joshua Choi, Danan Li, Evan Rogers, Anindya Sarkar, Levan Darjania, Geoffrey Oxnard, Jean Cui
• 5121 · PDF Targeting peripheral alpha 2A -adrenoceptors as a dual-benefit approach for integrated cancer therapy and supportive care Zhiqiang Cheng, Yang Xu, Larry Zhu
• 5122 Regulating m6A-RNA modification as new therapies for cancer Tariq Rana
• 5123 · PDF C018, a potent and selective CDK4&9 dual inhibitor Jinwen Huang, Zhongyuan Li, Steve Shen
• 5124 · PDF Identification and structural characterization of a novel PCNA-interacting small molecule scaffold Jennifer Jossart, Ning Ma, Pouya Haratipour, Caroline Li, Long Gu, Terrence O'Brien, Nagarajan Vaidehi, Linda H. Malkas, Robert Hickey, Jeff J. Perry
• 5125 · PDF Discovery of a novel, selective brain penetrant CDK4 inhibitor for targeted cancer therapy Boris Rogovoy, Dmitrii Shkil, Ruben Karapetian, Elena Bulanova, Alexei Rjakhovskiy, Sergey Shevyakov, Tudor Oprea, Amy Burd, Iain Dukes, Nikolay Savchuk
• 5127 · PDF Structure-guided discovery of potent and selective DGKalpha inhibitors for targeted cancer therapy Farag E. S. Mosa, Khaled Barakat
• 5128 · PDF Accelerated discovery of novel RORgammaT modulators using an AI-driven platform integrating generative chemistry and mechanistic PK simulation Jeremy Jones, Rafal Bachorz, Michael Lawless, Joanna Pastwinska, Anna Salkowska, Marcin Ratajewski
• 5129 · PDF Discovery and development of a novel PI3K-CDK4/6 dual inhibitor PC-13 for the treatment of breast cancer Xinyun Zhang, Jiaqi Hu, Xiaoxue Li, Qian Wang, Yanan Zhao, Qiang Xia, Jinhua Wang, Heng Xu, Tj (Tiejun) Bing
• 5130 Identification and characterization of pan-mutant selective PI3Kalpha inhibitors with the capability of PI3Kalpha H1047R protein degradation Chengshan Niu*, #, Shengli Dong*, #, Shaoqing Chen*, Kaige Ji, Zhengfei Guo, Maolin Zheng, Mingtao Chen, Yuanjie Li, Meihua Li, Hongqiang Li, Yu Yu, Xinlong Yang, Zhiyong He, Apeng Liang, Zhou Yin, Wei Wu, Jun Li*, Yusheng Wu
• 5131 · PDF HDM2021, a potent and selective CBL-B inhibitor exhibits robust immunomodulatory efficacy for anti-tumor therapy Shulun Chen, Mengting Zhao, Zhimin Zhang, Jingwen E, Xi Yang, Xinyu Dai, Zhenna Xia, Xin Xu, Dongzhou Liu
• 5132 · PDF Discovery and preclinical evaluation of a potent, orally bioavailable, highly selective, small molecule non-covalent KRAS[G12D] inhibitor Alexei Pushechnikov, Volodymyr Kysil, Ruben Karapetian, Stepan Mochalov, Aleksei Riakhovskii, Elena Bulanova, Nikolay Savchuk, Iain Dukes
• 5133 · PDF Design, synthesis and pharmacological evaluation of ACC1 selective inhibitors for cancer treatment Ryo Mizojiri, Moriteru Asano, Daisuke Tomita, Hiroshi Banno, Noriyuki Nii, Masako Sasaki, Hiroyuki Sumi, Yoshihiko Satoh, Yukiko Yamamoto, Takeo Moriya, Yoshinori Satomi, Hironobu Maezaki
• 5135 · PDF Targeting EGFR cysteine 775 in EGFR mutant lung cancer Jie Jiang, Zhengnian Li, Yaning Wang, Stephen J. Collins, Felix H. Gottlieb, Prafulla C. Gokhale, Michael J. Eck, Pasi A. Jänne, Jianwei Che, Nathanael S. Gray, Tinghu Zhang
• 5136 · PDF Multi-targeted MNK inhibitors as anticancer agents for AML Sophie Derusha, Erika Lisabeth, Sonali Kurup
• 5137 · PDF KBD880 is a potent and selective GPC3 peptide binder for treatment of HCC Hongzhu Chu, Yang Chen, Yonggang Wei, Fei Ye, Jing Zhang, Zhiyong Li, Xiaoke Liu, Jiannan Cui
• 5138 · PDF Chemical optimization of an orally bioavailable macrocyclic peptide KRAS inhibitors that achieve KRAS selectivity by recognizing a single amino acid difference Mirai Kage, Hatsuo Kawada, Koji Takano, Atsushi Matsuo, Yoshihisa Murata, Satoshi Hashimoto, Minoru Tamiya, Tomoya Kotake, Shino Kuramoto, Takashi Yamano, Machiko Irie, Kazuhiro Ohara, Yuuji Sakurai, Kenichi Nomura, Yuya Morita, Ryuji Hayashi, Yuma Wakamiya, Kana Takei, Hiroshi Tanaka, Yoshikazu Nishimura, Hitoshi Iikura, Takuya Shiraishi, Mikimasa Tanada
• 5140 · PDF Development of hydrophilic and metabolically stable heterocyclic AOH1996 analogues for pediatric AML oral liquid formulations Pouya Haratipour, Melissa Valerio, Michaela R. Jacobs, Maryam Zangi, Long Gu, Caroline Li, Robert Lingeman, Jennifer Jossart, Jefferson J. Perry, Le Xuan Truong Nguyen, Linda H. Malkas, Robert J. Hickey
• 5141 · PDF ZMS-4084, a potent and selective WRN inhibitor induces significant tumor regression and sustained complete responses in MSI-H tumor models Weikun Wang, Guimei Yang, Liting Xue, Yao Guo, Wenjing Li, Renhong Tang, Zhengtao Li
• 5142 · PDF PRMT5 inhibitor SCR-6920 downregulates HIF-1alpha and exhibits synergistic antitumor activity with Bevacizumab Guimei Yang, Huixia Dou, Liting Xue, Yao Guo, Wenjing Li, Zhen Li, Zhengtao Li, Renheng Tang
• 5145 · PDF A novel highly potent multiple-RAS inhibitor ZMS-2195 efficiently blocks MAPK pathway activation and induces robust anti-tumor growth effects in preclinical models Zhengtao Li, Guimei Yang, Huixia Dou, Wei Zhu, Xiang Chen, Yao Guo, Wenjing Li, Liting Xue, Renhong Tang
• 5146 · PDF Discovery of a novel ALK inhibitor ZM-8195 that targets ALK compound mutations with superior TRK selectivity Zhen Li, Yajing Liu, Mengying Li, Jing Dai, Xuefeng Wang, Yuan Cheng, Xue An, Jing Chen, Jianan Wang, Yuandong Zheng, Wenjing Li, Liting Xue, Zhengtao Li, Renghong Tang
• 5147 · PDF A novel investigation of the cyclin A/B inhibitor ZMS-7506 demonstrates robust anti-tumor efficacy both in vitro and in vivo Guimei Yang, Ruina Wang, Weikun Wang, Liting Xue, Xiaokang Qin, Renhong Tang, Zhengtao Li

在完整检索应用中浏览本分会场 →